Pharmafile Logo
Pharmafocus logo
Advanced Search

glioblastoma

Showing 10 posts of 10 posts found.

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026
Research and Development Oncology, QV Bioelectronics, glioblastoma

QV Bioelectronics, a medtech business specialising in implants for cancer treatment, has announced that it has received £4.5m in funding …

News

Tracon shares data from phase 2 trial for glioblastoma treatment

June 12, 2024
Medical Communications Oncology, Tracon Pharmaceuticals, clinical tria, clinical trial, glioblastoma

Tracon Pharmaceuticals has announced the publication of its phase 2 clinical data for its DNA damage repair inhibitor drug candidate, …

News
Chemotherapy

FDA grants ODD to ABM Therapeutics’ treatment for patients with glioblastoma

August 3, 2023
Medical Communications ABM Therapeutics, ABM-1310, FDA, Oncology, glioblastoma

ABM Therapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ABM-1310. …

News
shutterstock

Scorpion venom added to CAR-T therapy increases efficacy in brain cancer, research shows

March 6, 2020
Medical Communications, Research and Development CAR-T, Cancer, brain cancer, glioblastoma, pharma

Chimeric antigen receptor T cell (CAR-T) therapy has gained much traction and attention in the past years for its innovative …

News

MS drug boosts effectiveness of cancer therapy in treating glioblastoma, study shows

August 9, 2019
Medical Communications MS, brain cancer, glioblastoma, oncology, pharma

The multiple sclerosis (MS) drug teriflunomide boosts the effectiveness of cancer drugs in treating glioblastoma, according to researchers from UC, …

News
abbvie_0

AbbVie terminates Phase 3 brain cancer study after Depatux-M shows no benefit

May 20, 2019
Research and Development, Sales and Marketing AbbVie, Cancer, Depatux-M, glioblastoma, pharma, trial failure

AbbVie has terminated a Phase 3 study of the efficacy of Depatux-M (depatuxizumab mafodotin) in the treatment of newly diagnosed …

News
vbl-big

VBL Therapeutics’ shares plummet on Phase 3 glioblastoma failure

March 9, 2018
Medical Communications, Research and Development VBL, VBL Therapeutics, glioblastoma, pharma, trial failure

Israeli drug development firm VBL Therapeutics has been left reeling after it announced that its lead oncology product ofranergene obadenovec, …

News
glioblastoma

ImmunoCellular awarded $19.9 million grant for ICT-107 phase 3 trial for glioblastoma

September 25, 2015
Research and Development California Institute for Regenerative Medicine, Cancer, ICT-107, brain cancer, glioblastoma

ImmunoCellular Therapeutics has been awarded a $19.9 million grant by California Institute for Regenerative Medicine (CIRM), California’s stem cell agency, …

News

Merck KGaA readies phase III brain cancer trial

June 13, 2011
Research and Development Merck KGaA, brain cancer, cilengitide, glioblastoma

Merck KGaA has completed patient enrollment for a phase III global trial of its first-in-class integrin inhibitor in a rare …

News

Brain cancer vaccine to move into phase III

November 24, 2010
Research and Development, Sales and Marketing Celldex, Pfizer, brain cancer, glioblastoma

Celldex will press ahead with large-scale trials of its vaccine treatment for brain cancer after encouraging phase II results. The …

News
The Gateway to Local Adoption Series

Latest content

Thermo Fisher opens new distribution centre in Ireland

March 12, 2026

Altimetrik appoints Dhirendra Nath as Chief Human Resources Officer

March 12, 2026

Kindeva appoints Mike Cowhig as Chief Legal Officer

March 11, 2026

DiaMedica gets regulatory clearance from Health Canada for phase 2 preeclampsia study

March 11, 2026

Abselion establishes a US subsidiary in Massachusetts 

March 10, 2026